Wang Xuemei, Breaks Jennifer, Loutzenhiser Kathy, Loutzenhiser Rodger
Smooth Muscle Research Group, Department of Pharmacology and Therapeutics, University of Calgary Faculty of Medicine, Calgary, Alberta, Canada.
Am J Physiol Renal Physiol. 2007 Mar;292(3):F999-F1006. doi: 10.1152/ajprenal.00343.2006. Epub 2006 Nov 7.
The Na(+)/K(+)/2Cl(-) cotransporter (NKCC) plays diverse roles in the kidney, contributing sodium reabsorption and tubuloglomerular feedback (TGF). However, NKCC is also expressed in smooth muscle and inhibitors of this transporter affect contractility in both vascular and nonvascular smooth muscle. In the present study, we investigated the effects of NKCC inhibitors on vasoconstrictor responses of the renal afferent arteriole using the in vitro perfused hydronephrotic rat kidney. This preparation has no tubules and no TGF, eliminating this potential complication. Furosemide and bumetanide inhibited myogenic responses in a concentration-dependent manner. Bumetanide was approximately 20-fold more potent (IC(50) 1.0 vs. 20 micromol/l). At 100 and 10 micromol/l, furosemide and bumetanide inhibited myogenic responses by 72 +/- 4 and 68 +/- 5%, respectively. The maximal level of inhibition by bumetanide was not affected by nitric oxide synthase inhibition (100 micromol/l N(G)-nitro-l-arginine methyl ester). However, the time course for the dilation was slowed (from t(1/2) = 4.0 +/- 0.5 to 8.3 +/- 1.7 min, P = 0.04), suggesting either a partial involvement of NO or a permissive effect of NO on relaxation kinetics. Bumetanide also inhibited ANG II-induced afferent arteriolar vasconstriction at similar concentrations. Finally, NKCC1, but not NKCC2, expression was demonstrated in the afferent arteriole by RT-PCR and the presence of NKCC1 in afferent arteriolar myocytes was confirmed by immunohistochemistry. In concert, these results indicate that NKCC modulation is capable of altering myogenic responses by a mechanism that does not involve TGF and suggest a potential role of NKCC1 in the regulation of vasomotor function in the renal microvasculature.
钠/钾/2氯协同转运蛋白(NKCC)在肾脏中发挥多种作用,参与钠重吸收和球管反馈(TGF)。然而,NKCC也表达于平滑肌,该转运蛋白的抑制剂会影响血管和平滑肌的收缩力。在本研究中,我们使用体外灌注的肾积水大鼠肾脏,研究了NKCC抑制剂对肾传入小动脉血管收缩反应的影响。该制备物无肾小管且无TGF,消除了这一潜在并发症。呋塞米和布美他尼以浓度依赖的方式抑制肌源性反应。布美他尼的效力约高20倍(半数抑制浓度[IC50]为1.0对20 μmol/L)。在100和10 μmol/L时,呋塞米和布美他尼分别将肌源性反应抑制了72±4%和68±5%。布美他尼的最大抑制水平不受一氧化氮合酶抑制(100 μmol/L Nω-硝基-L-精氨酸甲酯)的影响。然而,舒张的时间进程减慢(从半衰期t1/2 = 4.0±0.5分钟至8.3±1.7分钟,P = 0.04),这表明一氧化氮可能部分参与其中,或者一氧化氮对舒张动力学有允许作用。布美他尼在相似浓度下也抑制血管紧张素II诱导的传入小动脉血管收缩。最后,通过逆转录聚合酶链反应(RT-PCR)在传入小动脉中证实了NKCC1而非NKCC2的表达,免疫组织化学进一步证实了传入小动脉肌细胞中存在NKCC1。综合来看,这些结果表明NKCC调节能够通过不涉及TGF的机制改变肌源性反应,并提示NKCC1在肾微血管血管舒缩功能调节中可能发挥潜在作用。